Trump Live Updates: FDA Peptide Meetings, Tariffs and Latest News
FDA advisory panels are currently debating the regulatory path and clinical viability of peptides following efforts to increase access to the controversial drugs.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
FDA advisory committees are weighing the legal status of peptides, resulting in mixed outcomes during recent sessions. While advisers have signaled support for a formal legal path for certain peptides, the panel also voted to reject the drug emideltide.
Coverage from Politico, Fortune, The New York Times, The Atlantic, and Fierce Pharma highlights ongoing tensions between administrative efforts to reduce regulatory barriers and scientific objections regarding safety and efficacy. Reporting notes that RFK Jr. has sought to alter current agency policies.
Future developments depend on the FDA's formal response to advisory recommendations. Coverage does not yet specify how the agency will reconcile the recent rejection of emideltide with the broader push to legalize other peptides.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
What is the current status of peptides at the FDA?
Advisory panels are currently reviewing peptides, having endorsed a potential legal path for some while voting down others like emideltide.
What role does RFK Jr. play in this process?
According to Politico, RFK Jr. has advocated for reducing what he describes as the aggressive suppression of these drugs.
How have experts responded to the peptide push?
Scientific experts have raised objections to the move, though advisory panels narrowly backed the peptide push in some instances.
Coverage (6)
- RFK Jr. promised to stop the ‘aggressive suppression’ of these controversial drugs. He’s making progress. Politico · 2h ago
- RFK Jr.'s peptide push narrowly gains backing from FDA advisers despite objections from scientists Fortune · 2h ago
- What to Know About Peptides the FDA Is Considering for Use The New York Times · 2h ago
- Peptide adcomm Day 2: Emideltide voted down in panel's 1st pushback Fierce Pharma · 3h ago
- America Is About to Go Over a Peptide Cliff The Atlantic · 6h ago
- FDA advisers endorse legal path for peptides Politico · 6h ago
Topics
From around our network
- Rescission Packages, Explained: The Route Trump Bypassed daybreakwire.com
Related trends
Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
Sanofi is scrapping trials for an eczema drug derived from its billion-dollar acquisition of Kymab following a pipeline review.
An FDA Panel Just Endorsed These Unproven Peptides
An FDA advisory panel has voted to permit the use of unproven peptides, sparking a conflict with agency scientists.
U.S. health officials investigate new outbreak of parasite cyclospora
U.S. health officials are investigating a widespread outbreak of the diarrhea-causing parasite cyclospora across nine states.
FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list
An FDA advisory committee has voted to add the popular peptide BPC-157 to the drug compounding list despite agency opposition.
Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average
Eli Lilly is moving toward FDA approval for its weight loss drug retatrutide following successful Phase 3 trial results.
Target, Kroger, Meijer fruit purée pouches recalled over plastic risk: FDA
Major retailers including Target, Kroger, and Meijer are recalling PT Organics fruit purée pouches due to potential plastic contamination.